TGN: Florida Institute finalizes funding agreement with TransGenex Nanobiotech
The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with TransGenex Nanobiotech, Inc., a company that is developing nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.
Read full article »
Co-Founder
Shyam Mohapatra
TGN is a provider of drug-resistant tumor catalyzing and customized cancer tests.
Read more